Drug-specific tumor-specific drug test shows signs of efficacy

Drug-specific tumor-specific drug test shows signs of efficacy

Dublin, Ireland: Treatment with capivasertib, a drug that works against a specific gene mutation found in some tumors, shows signs of efficacy in a study of 35 patients today (Tuesday) at the 30th EORTC-NCI-AACR Symposium Molecular targets and cancer therapeutics were presented in Dublin, Ireland.

The Phase 2 trial (EAY131-Y) is part of a larger US study called NCI-MATCH (EAY131) to determine whether cancer patients can be successfully treated by selecting therapies that target their tumors Gene anomalies found target to cancer.

Researchers say their findings provide further evidence that the approach to tailoring treatment to tumorigenesis could provide more effective treatments for individual patients in the future. The more traditional approach is to treat patients based on what has worked in the past for other patients with the same type of cancer.

The research was Kevin Kalinsky, Assistant Professor of Medicine at New York's Presbyterian-Columbia University Center, Irving, USA. He said, "Capivasertib can be taken orally, a type of drug called an AKT inhibitor, which means it binds to a molecule called AKT that mutates a change that plays a role in the growth of cancer cells Capivasertib has shown potential in treating an aggressive form of breast cancer in earlier phase 2 study.

"In this study, we wanted to find out if Capivasertib can be used in patients with any type of cancer whose tumors have the mutation that causes the AKT molecule to become overactive and cause the cancer to grow."

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.